Premium-priced Tresiba starts on strong note in India?
This article was originally published in Scrip
Executive Summary
Novo Nordisk's once-daily basal insulin therapy Tresiba (insulin degludec) appears to have made its Indian debut priced at a premium compared with certain Western markets – perhaps turning conventional thinking on the differential pricing model in emerging markets on its head.